Terazosin Capsule
Product Images NDC 71335-9607

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 71335-9607). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 01)

Chemical structure diagram of terazosin hydrochloride dihydrate, showing the molecular formula C19H25N5O4 with associated hydrochloride and water molecules, and a molecular weight of approximately 459.93.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 02)

A table comparing symptom score and peak flow rate changes for terazosin versus placebo across three clinical studies with different dosing regimens and durations. The table includes baseline mean values and mean changes (in percentages) for both symptom score and peak flow rate, highlighting significant improvements with terazosin over placebo.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 03)

Two line graphs comparing terazosin and placebo groups over three months from baseline. The left graph shows mean change in total symptom score, with terazosin decreasing symptoms more than placebo. The right graph shows mean increase in peak flow rate (mL/sec), with terazosin demonstrating greater improvement than placebo. Both include error bars and sample sizes.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 04)

A line graph titled 'Mean Change in Total Symptom Score from Baseline' from a long-term, open-label, non-placebo controlled study with 494 subjects. The x-axis represents time in months (0 to 30), and the y-axis shows mean change from baseline in symptom score (0 to -7). Data points indicate a decrease from 0 to around -5 over time, with multiple statistically significant changes (p ≤ 0.05) marked by asterisks. The mean baseline symptom score was 10.7.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 05)

A line graph titled 'Mean Change in Peak Flow Rate from Baseline' from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis shows months from 0 to 30, and the y-axis shows mean change from baseline in mL/sec ranging from 0.0 to 4.5. The graph includes data points with error bars and asterisks indicating statistical significance (p ≤ 0.05) compared to baseline, demonstrating an increase in peak flow rate over time.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 06)

A table showing mean changes in systolic and diastolic blood pressure (SBP and DBP) from baseline to final visit in double-blind placebo-controlled studies for normotensive (DBP ≤ 90 mmHg) and hypertensive (DBP > 90 mmHg) patients. The table compares placebo and terazosin groups, presenting sample sizes (N) and mean changes in mmHg, with statistical significance indicated for terazosin versus placebo.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 07)

A table titled 'Adverse Reactions During Placebo-Controlled Trials Benign Prostatic Hyperplasia' showing percentages of adverse reactions by body system for terazosin (N=636) versus placebo (N=360). It lists reactions under body as a whole, cardiovascular, digestive, metabolic and nutritional disorders, nervous, respiratory, special senses, and urogenital systems, with percentages of each reaction occurrence in terazosin and placebo groups, including statistical significance indicators.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 08)

A data table presenting discontinuation rates during placebo-controlled trials of terazosin in benign prostatic hyperplasia. It lists body systems and related adverse events such as fever, headache, postural hypotension, syncope, nausea, dizziness, vertigo, dyspnea, blurred vision, and urinary tract infection, comparing percentages for terazosin (N=636) and placebo (N=360) groups.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 09)

Table presenting adverse reactions during placebo-controlled trials for hypertension, comparing terazosin (N=859) and placebo (N=506). The table lists body systems affected, including body as a whole, cardiovascular, digestive, metabolic and nutritional, musculoskeletal, nervous, respiratory, special senses, and urogenital, with percentages of occurrence for various symptoms under each system.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 10)

A data table titled 'Discontinuation During Placebo-Controlled Trials Hypertension' comparing adverse event discontinuation rates between Terazosin (N=859) and placebo (N=506). The table lists body systems and associated symptoms with percentages of discontinuations, showing higher rates in Terazosin for most symptoms such as asthenia, headache, palpitations, dizziness, and blurred vision.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 12)

FDA Label Image

Label (Lbl713359607)

Label for Terazosin 10 mg capsules by Bryant Ranch Prepack, with a package count of 30 capsules. The label includes a comparison to Hytrin 10 mg capsules by Avet Pharmaceuticals Labs Inc. It notes the capsule is blue and white and specifies storage at room temperature 20°-25°C (68°-77°F). The NDC code 71335-9607-1 is displayed along with lot number 1523487 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.